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Abstract 
The cDNA for ATPlALl - the fifth member of the human Na,K-/H,K-ATPase gene family ~ was cloned and sequenced. The deduced primary 
ATPlALl translation product is 1,039 amino acids in length and has M, of 114,543. The encoded protein has all of the structural features common 
to known catalytic subunits of P-type membrane ion-transporting ATPases and is equally distant (63-64% of identity) from the Na,K-ATPase 
isofonns and the gastric H,K-ATPase. The ATPl AL1 encoded protein was proposed to represent a new separate group within the family of human 
potassium-dependent ion pumps. 
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1. Introduction 
Among various cation-transporting ATPases which 
form phosphorylated intermediates during the catalytic 
cycle (P-ATPases), two groups possess the most similar- 
ity in structural and functional properties. These are the 
Na,K-ATPase, a universal component of animal cell 
plasma membranes, and the H,K-ATPase, a pump spe- 
cific to the parietal cells of the gastric mucosa. These 
enzymes can be thought of as belonging to one group 
designated as the X,K-ATPases. A gene family, com- 
posed of six closely related genes was identified in the 
human genome [1,2]. Three of them were shown to en- 
code the oil, a2 and a3 isoforms of the Na,K-ATPase 
catalytic subunit while a fourth encodes the catalytic 
subunit of the gastric H,K-ATPase. The functional 
status of the remaining two genes designated as 
ATPlALl (described also as SW 3.2 [l] and aD [2]) and 
ATPlAL2 (aC [2]) was unknown [3]. Further studies 
resulted in the isolation, mapping and partial sequencing 
of the ATPlALl gene and further demonstrated that it 
is expressed in human brain and kidney, at least [4]. The 
limited sequence information allowed us to suggest that 
the gene probably encodes a novel type of ion pump 
rather than an isoform of known ones [4]. Here, we 
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report the nucleotide and deduced amino acid sequences 
corresponding to the ATPlALl gene coding region. The 
protein sequence comparison demonstrates that 
ATPlALl protein- the fifth member of the human X,K- 
ATPase family - is equally distant from the Na,K-ATP- 
ase isoforms and gastric H,K-ATPase, and together with 
the putative rat distal colon and toad bladder H,K- 
pumps [5,6] belongs to the third separate group within 
the family of the X,K-ATPases. 
2. Experimental 
2.1. Total andpoly(A)’ RNA preparation, cDNA library screening 
and cDNA sequencing 
Total cellular RNA from frozen human tissue (except skin) was 
isolated by the guanidine thiocyanate method according to a protocol 
in [7]. Total cellular RNA from the skin samples was purified by the 
acid phenol method [8]. The poly(A)‘-RNA was isolated as previously 
described [4]. 
The oligo(dT) and random-primed cDNA was generated following 
the nrotocol in 19.101. Double stranded cDNA was inserted into plas- 
mid pBR322 cleaved with PstI by the dG: dC tailing technique [7], or 
was cloned into the EcoRI site of the phage vector AgtlO or plasmid 
pSP64 (#P1091, Promega Corp., Madison, WI, USA) according to 
procedures supplied by the manufacturer (1gtlO cDNA cloning kit, 
#RPN1713, Amersham Corp., Arlington Heights, IL). cDNA libraries 
were screened by hybridization with ‘*P-labeled oligonucleotides. The 
oligonucleotide radiolabeling, hybridization, restriction analysis, sub- 
cloning and purification of DNA were carried out as in [7]. The nucle- 
otide sequencing of all of the cDNA fragments was performed on both 
strands by the dideoxy chain termination method [l 1] using Sequenase 
Version 2.0 DNA Sequencing Kit (#70770, United States Biochem. 
Corp., Cleveland, OH, USA). 
Computer analyses of the nucleotide and protein sequences were 
performed using DNASTAR (DNAStar Inc., Madison, WI, USA) and 
UWGCG package (Genetics Computer Group, Madison, WI, USA) 
program pockets. 
2.2. PCR-amplification and oligonucleotides 
For PCR amplification Taq and Tth (NMDCentr, Moscow, RF), 
Vent (New England Biolabs, Inc., Beverly, MA, USA) and Pfu 
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(STRATAGENE Cloning Systems, La Jolla, CA, USA) DNA polym- 
erases were used. The reaction was performed as previously described 
[4] with modifications. Briefly, random-primed cDNA was generated 
from 1 pg of the total or 0.5 pg of poly(A)’ RNA following a standard 
technique [7] and one tenth of the synthesized cDNA was subjected to 
30 cycles of enzymatic amplification at 95°C 0.5 min; 55-60°C 
0.5 min; and 72”C, 2 min. 
For the race amplification of the 5’ region of the mRNA of interest 
(S-RACE) cDNA was generated from 0.5-l pg of the total or of 
poly(A)’ RNA with oligonucleotide 830, as a primer, as described 
above [7]. After this step the protocol described in [12] was followed, 
except the low melting agarose electrophoresis and anion-exchanging 
chromatography stages for the separation of the cDNA first chain from 
the excess of primer were omitted, and oligonucleotide 825 was used 
as a gene-specific primer in PCR amplification reaction. 
The PCR-generated fragments were blunted with T4 DNA polym- 
erase [7] and cloned into SmaI-cut pUCl8 and sequenced by the dide- 
oxy method [ll]. 
The ohgonucleotide used in this study listed below with coordinating 
cDNA positions in parenthesis: pU69, S-AGATTCCGAGAAGAA- 
GACCA-3’ (464483); pU70, S-GCTGGGGCTCAGACTCCCCCG- 
TGAGA3’ (696721); 825, 5’-CAAGCACACAGCCCAAGTAC-3 
(435454); 826, 5’-AAGGTACCAGAGGGAATACCT-3’ (2,766 
2,786); 827, S-GTAGCCCGTCCATTCTAGGTAT-3’ (2,781-2,802); 
828, S-GACCCTGTCGCTGACAGCA-3’ (1,071-1,089); 829, (com- 
plementary to 828) S-TGCTGTCAGCGACAGGGTC-3’; 830, 5’- 
CCGTTAAAATGACCACCAGACC-3’ (454475); 893, GGATGCC- 
AAGGCCGCTGTGGTGAC-3’ (2,019-2,042); 894, S-CAGCTCCA- 
TGCCAGTCACCACAGC-3’ (2,032-2,055); 983, 5’-TGGTGATGA- 
AGGGCGCCC-3’ (1,559-1,577); 984, (complementary to 983) 5’- 
GGGGCGCCCTTCATCACCA-3’. Information for the synthesis of 
oligonucleotides used in present experiments was obtained by compar- 
ison of genomic sequence data obtained in previous studies [1,4] with 
other human P-ATPases. The sequence for the synthesis of the oligonu- 
cleotides 983 and 984 was chosen based on the codon preference usage 
[13] (see section 3.1). The ‘GGC’ codon for Gly’” was chosen as the 
most frequently used, and the cytidine at third position is substituted 
for G in the cloned cDNA sequence. 
3. Results and discussion 
3.1. Isolation and sequence analysis of the ATPlALl 
cDNA from human kidney and skin 
In order to isolate the ATPlALl cDNA we prepared 
and screened two human kidney libraries (randomly and 
oligo(dT) primed, about 450,000 colonies in sum) with 
gene-specific oligonucleotides (826 and 830 - see Fig. 1). 
Two individual clones (pHK 14 and pHK12, Fig. 1) that 
gave reproducible positive hybridization signals with ol- 
igonucleotide 826 were isolated. Sequence analysis 
showed that these cDNAs included 596 bp from 3’-end 
of the coding region plus 290 nucleotides from the 
3’-untranslated region, including the poly(A) tail. Several 
attempts to isolate other positive clones with different 
gene-specific oligonucleotides from this and two others 
kidney libraries (in ygtl0 vector, -2.5 x lo6 clones in 
total) were unsuccessful. 
To overcome this problem we undertook PCR-based 
amplification employing gene-specific oligonucleotides. 
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Fig. 1. Restriction map and cloning and sequencing strategy for the human ATPIALI cDNA. The black and shaded rectangles represent coding 
regions and hatched rectangles represent untranslated regions. The shaded rectangles correspond to the genomic sequence of the ATPALl exons, 
determined earlier [4]. The black bars represent cDNA fragments obtained in PCR-amplification experiments (above colour-coded rectangle) or 
cloned from non-amplified human cDNA libraries (below). PCR-fragments with numbers were amplified from poly(A)’ RNA fraction from kidney 
and with numbers plus ‘IS’ - from the total cellular RNA from armpit skin (see text). The gene-specific oligonucleotides that were used as PCR and 
sequencing primers are shown by arrowheads. The direction and extent of sequencing are indicated by arrows. Nucleotide sequence of the pHK12 
cDNA was determined only for the corresponding PCR fragment obtained in the amplification reaction of the original plasmid with 826 and oligo(dT) 
primers, since the cDNA insert could not be excised from the cloning vector. 
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As a result, several ATPlALl cDNA fragments that 
overlapped 1,837 nucleotides of the mRNA of interest, 
including 71 bp of the predicted 5’-untranslated region 
(see Figs. 1 and 2), were cloned and sequenced. The 
sequence corresponding to the region between nucleo- 
tides 1,256 and 2,135 was not recovered, despite the use 
of different DNA polymerases and attempts to optimize 
the PCR-reaction conditions (see section 2). The PCR- 
fragment for the 5’-half of this region, but not for the 
3’-half (Fig. l), was isolated using two oligonucleotides 
(983 and 984) corresponding to the FITC binding site 
which is characteristic of the ion-motive P-ATPase 
family [14] (Fig. 3). Presumably, the region between nu- 
cleotides 1,570 and 2,135 contained some kind of ‘stop’- 
sequence(s) for the polymerases used in these experi- 
ments. 
there was no indication of any alternative splicing of the 
ATPl AL transcript. 
At present, the actual molecular size of the ATPlALl 
mRNA remains to be determined. Possibly due to actual 
low number of the mRNA copies in poly(A)’ RNA from 
brain and kidney and nontypical low relative content of 
poly(A)’ fraction in the skin total RNA, no positive 
signal could be detected by Northern blot analysis using 
different specific probes (data not shown). 
A search for the ATPlALl transcript in different 
human tissues and organs revealed the presence of the 
mRNA of interest in skin samples from several specific 
areas, including axilla (Akopyanz N.S., Grishin A.V. et 
al., manuscript in preparation). Presumably, the 
ATPlALl protein is a component of sweat glands 
(ibid.). The relative abundance of this mRNA was higher 
in this tissue than in all others examined. Therefore, 
RNA of this tissue was chosen for further cloning exper- 
iments. In spite of the low content of the poly(A)‘-frac- 
tion in this tissue (less than 0.3%), we were able to obtain 
a cDNA library of 2.4 x lo5 independent clones which 
was screened with two oligonucleotides (828 and 894, 
Fig. 1). As a result, two clones (pHAS 34.1 and pHAS 
58.1, Fig. 1) were isolated and sequenced. The cDNA 
insert from the pHAS 34.1 plasmid was of 3,403 base 
pairs and contained the entire coding part of the gene as 
well as 5’- and 3’-untranslated regions (Fig. 1). It allowed 
us to bring together all of the sequence information that 
had been obtained earlier. No differences between skin 
and kidney cDNAs and the known genomic sequences 
([4], ad Sverdlov et al., unpublished) were revealed, and 
The composite restriction map and cloning and DNA 
sequencing strategy for the human ATPlALl gene en- 
coded cDNA are presented in Fig. 1. The nucleotide 
sequence of the 5’- and 3’-untranslated regions and de- 
duced amino acid sequences are shown in Fig. 2 and 
Fig. 3, respectively. The cDNA consists of 3,574 nucleo- 
tides and includes a protein coding region of 3,117 nucle- 
otides that is preceded by a 168-nucleotide 5’-untrans- 
lated sequence and followed by a 3’-untranslated region 
of 290 nucleotides. The predicted initiation methionine 
codon is the first ATG-codon and is preceeded by non- 
interrupted open reading frame which we believe to rep- 
resent mRNA S-untranslated sequence. The 3’-untrans- 
lated sequence includes a poly(A)-tail which is preceded 
by the AAAAAA sequence that has been shown to be a 
very rarely used but functional polyadenylation signal 
11% 
3.2. Structural features of the ATPlALI protein and its 
relationship with other X,K-ATPases 
The primary ATPlALl gene translation product de- 
duced from the cDNA sequence (Fig. 3) consists of 1,039 
amino acid residues and has a A4, of 114,543. This new 
human protein has all structural features of an ion-trans- 
porting P-ATPase. These include several conserved mo- 
tifs such as a catalytic phosphorylation site (As~~~‘*[ 17]), 
components of the ATP-binding site (Asp732 and Asp736 
[18]), the target of FITC modification (Lys523 [14]), and 
the very characteristic disposition of potential trans- 
membrane domains [14]). The alignment of the deduced 
protein sequences of the catalytic subunits of all five 
human X,K-ATPases and two others which are homolo- 
gous to the ATPlALl protein (putative rat colon and 
toad bladder H,K-ATPases) is shown in Fig. 3. 
S- UTR 
CGGCCGCGGAGGTGCGTGCAGGGCCCGCGCCGCCGCCGCTC 
AGCCACTGCCACTGCCACAGCCACACGAGGCCCCCCACCGC 
CCGGATCCGCGCTCCACGCCCGCAGCCCGCGGCGCCACCAGCCCAGCAX 
3’4JTR 
~GACCACCTCCCTTCCTATGTCTCTCAGCAGCACGTTGGGGCACACTTGl-KATCTTC 3177 
TGACCGTTTGCTGGGCTATTCCCCTGCAGlGCAGACATCGTCAAAATTCATACAAGAGGA 3237 
AAlTl-KATGCAGMAGCTGTATGCAGGATGCTCACTGATGTTllGCACTTTAAAACTGA 3297 
AATTCAACTCmATATAGGAlTTTCTTTTCTATCTCCATCTCCKA~MAMATACGT 3357 
ACATTTCGAGGTAATGGTATAAAAAAAAAAAAAAAAAAAA 3407 
-108 
-48 
3 
Fig. 2. Nucleotide sequence of the 5’- and 3’-untranslated regions (5’- 
UTR and 3’-UTR, respectively) of the human ATPlALl cDNA. The 
predicted initiation ATG and TAA-stop codons, and potential polyad- 
enylation site are underlined. Nucleotides numbered at the right of the 
sequences, and coordinates are indicated according to the complete 
cDNA sequence, which is available in the GenBanklEMBL Data Bank 
with Accession Number UO2076). 
ATPlALl exhibits 63.1l64.2% amino acid identity to 
the catalytic subunit of human gastric H,K-ATPase and 
the three a-isoforms of human Na,K-ATPase. Thus, the 
ATPlAll protein is equally distant and related to both 
of the above groups and can not be assigned as an 
isoform of any of them. The same level of sequence 
similarity was demonstrated for the related family of five 
rat ATPases [5]. The toad bladder H,K-ATPase alpha is 
67% identical to the toad Na,K-ATPase a-subunit [6]. 
The sequence comparison of new human, rat and toad 
*Here and throughout, all amino acid numbering is indicated accord- 
ing to the ATPl AL1 encoded protein sequence (Fig. 3). 
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Fig. 3. Comparison of the amino acid sequences of the human ATPI AL1 encoded protein (X,Kh) and of the catalytic subunits of the putative rat 
distal colon H,K-ATPase (H,Kc) [5], toad bladder H,K-ATPase (H,Kb) [6], human gastric H,K-ATPase (H,Kg) [19,20], and the human a,-, cz2-. and 
a,-isoforms of Na,K-ATPase (N,Kl, N,K2, and N,K3, respectively) [21-231. Gaps (represented by dashes) were introduced to maintain the alignment. 
Dots indicate identity to the corresponding residues of the human ATPl AL1 putative protein. Hydrophobic sequences that meet the criteria for 
consideration as potential transmembrane domains (determined by the method of [16]) are underlined and labeled. The phosphorylation site, the 
binding site for FITC and ClATP (AsP’~* and AsP”~) [18] are overlined. Amino acid residues which were shown to be important for binding of ouabain, 
Sch 28080 and omeprazole indicated by an asterisk (*). The charged amino acids residues located within the predicted transmembrane segments are 
indicated by filled diamonds (+ - which are preserved, or conservatively substituted, in all proteins) or by filled triangles (- - which are not preserved 
in all sequences). The amino acids are numbered at the right of the sequences. 
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ATPases revealed that ATPl AL 1 exhibits 86.1% of over- 
all identity with rat colon pump and both mammalian 
enzymes are about 75% identical to the toad bladder 
H,K-ATPase. In contrast, the human and rat Na-pump 
a-isoforms and human and rat gastric H,K-ATPases 
each exhibit 96.7-99.1% homology to one another. 
About 93% of the toad Na,K-ATPase a-subunit amino 
acid sequence is identical to the rat and human al- 
isoform. On the other hand, the Na,K-ATPase al, a2 
and 013 from the same organism share 8687% identical 
amino acids. The relationships of these sequences are 
presented as dendrograme in Fig. 4. Obviously, the 
ATPl ALl-encoded protein, the rat colon pump and the 
toad bladder H,K-ATPase represent one class of homol- 
ogy which is distant both from the Na,K- and gastric 
H,K-ATPases. However, members of this third group 
are more divergent than related enzymes. This may indi- 
cate that sequence requirements for the ATPlALl pro- 
tein, putative rat colon and toad bladder H,K-ATPases 
were not as rigid during evolution, as was the case for 
the extremely well-conserved H,K- and Na,K-ATPases. 
At present, the possibility that these proteins [5,6] are 
products of closely related but distinct genes can also not 
be excluded. 
The availability of three closely related sequences from 
different species allows us to dwell on the structural fea- 
tures specific to this group of ion-pumps (see also [5,6]). 
Thus, the alignment in Fig. 3 depicts a number of regions 
which are extremely conserved in all of the X,K- 
ATPases. The domains can be defined in coordinates of 
the ATPlALl amino acid sequence as 225-240,337412, 
491-508, 521-538, 556-576, 591-650 and 702-796 
(Fig. 3). In addition, fragments 94132, 144189, 200- 
221,804852,947-968, 1,012-1,023 form a group of less 
conserved but still homologous sequences. Most of these 
sequences are located in major cytoplasmic domains 
(H2-H3 and H4H5), that were shown to be involved in 
ATP-binding or catalytic activity (see Fig. 3 and above), 
but cover also several transmembrane segments, includ- 
ing Hl, H2, H4 and part of the H5-H6 pair. The essen- 
tial sequence peculiarity of the third group of pumps 
within the above regions is that in certain positions they 
all have amino acids residues characteristic of either the 
gastric H,K-ATPase or the sodium pump ol-isoforms. 
Large differences in the distribution of charged amino 
acid residues can be revealed upon comparison of hydro- 
phobic domains forming the putative cation-conducting 
pathway (Fig. 3). It was suggested that charged aspartate 
and glutamate residues could be involved in cation occlu- 
sion [28,29]. This appears to be the case for Glu*“, 
AsP~‘~, and Asp 830 that have been shown to be crucial for 
the Na,K-ATPase transporting activity [30,31]. All of 
them are preserved in all of the sequences in Fig. 3 except 
Aspsz6/Glu substitution in the gastric pump. The func- 
tional role of G1u349 and Asp948 which are conserved in 
all proteins, remains unclear [30]. In addition, several 
charged residues can be pointed out as characteristic of 
one of the groups - Aspsx3 and GIu~~’ (for gastric H,K- 
ATPase) and G1u976 and G1u977 ~ for Na,K-ATPase (but 
see [32]). On the other hand, the ATPlALl protein, rat 
colon pump and toad bladder H,K-ATPase bear differ- 
ent amino acid residues in each position where any of 
them has charged amino acid and there is no counterpart 
in the other sequence groups. For example, both the 
positions 3 18 and 8 12 are occupied either by Asp or Gly, 
and 944 ~ by Glu or Gln (Fig. 3). (This type of divergence 
is very characteristic also for extracytoplasmic part of 
polypeptide chains (Fig. 3)). This argues against the pre- 
sumed functional significance for these particular amino 
acid residues. There is only one common charged amino 
acid residue in the membrane portion of the gastric H,K- 
ATPase, the ATPlALl protein and the colon and blad- 
der pumps, namely LYS~~~. The toad bladder enzyme, 
when expressed in Xenopus oocytes in association with 
P-subunit was demonstrated to pump protons outside 
and potassium inside the cell 1141. Whether this amino 
acid participates in proton transport remains to be 
shown. 
The extracellular protein domain contributes to 
ouabain binding in the Na,K-ATPase [33-391 and the 
docking of Sch 28080 and omeprazole in the gastric H,K- 
ATPase [40]. It can been seen that the ATPlALl protein, 
rat colon and the toad bladder pumps share many amino 
acid residues that were shown to be important for 
ouabain binding - CYS’*~ [33,34], Tyr/Phe13’ [33], Tyr330 
[35], Thr”’ [36] and Arg9’* [37]. The non-charged constit- 
uents of the HI-H2 extracytoplasmic border residues 
[38,39] are also conserved (Fig. 3). One of those residues, 
the Phe13’, in concert with Asp13’ (which presents only in 
the gastric H,K-ATPase), was predicted to participate in 
the binding of Sch 28080 [40]. Interestingly, the toad 
bladder pump was inhibited by both ouabain and Sch 
28080 with Ki values of 25 PM and 230 PM, respectively 
[6]. The ouabain inhibition constants within the same 
order of magnitude were shown for the Na,K-ATPase 
a-subunit mutants which possessed at least one of the 
residues in positions 126, 130, 819 or 902 substituted 
[33,34,36,37] (see above), while in toad bladder enzyme 
they are all preserved. It demonstrates that many aspects 
of the inhibitor pump interaction remain unknown. 
Sensitivity to omeprazole within this family seems to 
be a unique feature of the gastric H,K-ATPase, since 
only this enzyme possesses three cysteine residues at po- 
sitions 819, 828 and 898 within the H5-H6 and H7-H8 
extracytoplasmic domains that were shown to bind this 
drug covalently [40]. Interestingly, in all other proteins 
cys*i9 is substituted by a Thr involved in ouabain bind- 
ing [36]. 
It can be seen that the most divergent region in the 
X,K-ATPases family is the extreme N-terminal domain 
(Fig. 3) that was shown to be important for cation bind- 
ing and occlusion in Na,K-ATPase [4143]. The right- 
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Fig. 4. Dendrogram of the amino acid sequences of the human 
ATPlALl encoded protein (Allhum) and of the catalytic subunits of 
the putative rat distal colon H,K-ATPase (Allrat) [5], toad bladder 
H,K-ATPase (Alltoad) [6], human (Ghkhum) [19,20] and rat (Ghkrat) 
gastric H,K-ATPases [24], toad Na,K-ATPase (All toad) [25] and the 
a,-, a,-, and a,-isoforms of the Na,K-ATPase from human [21-231 and 
rat [26] (Alhum, A2hum, A3hum, and Alrat, AZrat, and A3rat, respec- 
tively), was created by PILEUP program (GCG Package) using a sim- 
plification of the progressive method of Feng and Doolite [27]. Distance 
along the vertical axis is proportional to the difference between the 
sequences. 
most boundary of this domain appears to lie between 
Leus6 and Asp5’ that corresponds to the position of the 
second intron found in human genes encoding H,K- 
ATPase [19,20] and the Na,K-pump a3-isoform [23], as 
well as in the ATPlAll gene (Sverdlov et al., unpublished 
observation). In this region, ATPlALl exhibits only 
55.4% identity with the rat colon enzyme, and these two 
are 28.5% and 33% identical to the bladder pump, re- 
spectively. Such a low level of similarity for homologous 
proteins is nontypical for the X,K-ATPase family. For 
example, all other human and rat homologs share about 
90% identical amino acid residues with their correspond- 
ing rat homologs. Therefore, the prominent diversity be- 
tween ATPlALl, rat colon and bladder pumps resemble 
the relations between isoforms or even different enzymes 
rather than species difference among the same enzyme. 
On the other hand, it may indicate that there is not the 
same significant role for the N-terminal domain in these 
new enzymes (if they are not isoforms but homologs) 
which was found for Na,K-ATPase [4143]. 
All of the preceeding observations indicate that the 
sequence mosaic within functionally important domains 
may be seen as the most essential structural feature of the 
new subfamily formed by ATPlALl, putative rat colon 
pump and toad bladder H,K-ATPase. However, there 
are several conservative motifs (914-968,995-1,039) and 
amino acids (for example - G1y293, G1uM7, Lysss4 etc.) 
that could be considered as characteristic to this whole 
group. 
In conclusion, we have isolated and sequenced the 
cDNA for the human ATPlALl gene encoding a new 
member of the X,K-ATPases catalytic subunit family. 
The ATPlALl protein, rat colon pump [5] and the toad 
bladder H,K-ATPase [6] form a distinct group within 
this family. The sequence relationships between mem- 
bers of this group are more divergent than that for the 
other related groups, and it remains to be shown whether 
these proteins are products of closely related but distinct 
genes [5,6], or if the structure-function relationships 
within this subfamily are quite different. Both the blad- 
der pump [6] and the putative rat colon H,K-ATPase [5] 
were suggested to be involved in K’ homeostasis. One 
could thus propose that the ATPlALl gene encodes the 
catalytic subunit of the human non-gastric H,K-ATPase. 
Verification of this proposal is the aim of our current 
research. The requirement for any distinct beta-subunit 
for the normal enzyme activity, possible physiological 
role of the ATPlALl protein, and it’s pharmacological 
properties are also the goals of further study. 
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